dc.contributor.author |
Cabello, Paula |
dc.contributor.author |
Torres-Ruiz, Sandra |
dc.contributor.author |
Adam-Artigues, Anna |
dc.contributor.author |
Forés-Martos, Jaume |
dc.contributor.author |
Martínez, María Teresa |
dc.contributor.author |
Hernando, Cristina |
dc.contributor.author |
Zazo, Sandra |
dc.contributor.author |
Madoz-Gúrpide, Juan |
dc.contributor.author |
Rovira, Ana |
dc.contributor.author |
Burgués, Octavio |
dc.contributor.author |
Rojo, Federico |
dc.contributor.author |
Albanell Mestres, Joan |
dc.contributor.author |
Lluch, Ana |
dc.contributor.author |
Bermejo, Begoña |
dc.contributor.author |
Cejalvo, Juan Miguel |
dc.contributor.author |
Eroles, Pilar |
dc.date.accessioned |
2024-02-27T07:22:06Z |
dc.date.available |
2024-02-27T07:22:06Z |
dc.date.issued |
2023 |
dc.identifier.citation |
Cabello P, Torres-Ruiz S, Adam-Artigues A, Forés-Martos J, Martínez MT, Hernando C, Zazo S, Madoz-Gúrpide J, Rovira A, Burgués O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo JM, Eroles P. miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer. Cancers (Basel). 2023 Apr 4;15(7):2138. DOI: 10.3390/cancers15072138 |
dc.identifier.issn |
2072-6694 |
dc.identifier.uri |
http://hdl.handle.net/10230/59268 |
dc.description.abstract |
Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of microRNAs in the trastuzumab response, we performed a microRNA array in parental and acquired trastuzumab-resistant HER2-positive breast cancer cell lines. Our results identified miR-146a-5p as the main dysregulated microRNA. Interestingly, high miR-146a-5p expression in primary tumor tissue significantly correlated with shorter disease-free survival in HER2-positive breast cancer patients. The gain- and loss-of-function of miR-146a-5p modulated the response to trastuzumab. Furthermore, the overexpression of miR-146a-5p increased migration and angiogenesis, and promoted cell cycle progression by reducing CDKN1A expression. Exosomes from trastuzumab-resistant cells showed a high level of miR-146a-5p expression compared with the parental cells. In addition, the co-culture with resistant cells' exosomes was able to decrease in sensitivity and increase the migration capacities in trastuzumab-sensitive cells, as well as angiogenesis in HUVEC-2 cells. Collectively, these data support the role of miR-146a-5p in resistance to trastuzumab, and demonstrate that it can be transferred by exosomes conferring resistance properties to other cells. |
dc.format.mimetype |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
MDPI |
dc.relation.ispartof |
Cancers (Basel). 2023 Apr 4;15(7):2138 |
dc.rights |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/ |
dc.title |
miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer |
dc.type |
info:eu-repo/semantics/article |
dc.identifier.doi |
http://dx.doi.org/10.3390/cancers15072138 |
dc.subject.keyword |
HER2+ breast cancer |
dc.subject.keyword |
Exosomes |
dc.subject.keyword |
miR-146a-5p |
dc.subject.keyword |
Resistance |
dc.subject.keyword |
Trastuzumab |
dc.rights.accessRights |
info:eu-repo/semantics/openAccess |
dc.type.version |
info:eu-repo/semantics/publishedVersion |